Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YSCH-01 Monotherapy and in Combination With Atezolizumab in Recurrent Glioblastoma
NCT07538128Phase 1Recruiting
- Sponsor
- Huashan Hospital
- Start
- Jan 2025
- Primary completion
- Nov 2026
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of recombinant L-IFN adenovirus in glioblastoma (GBM) (2 arms), sponsored by Huashan Hospital. Primary endpoints: Incidence and Nature of Adverse Events and Serious Adverse Events and 1-year survival rate. Started Jan 2025; status: recruiting.
02
Drugs
recombinant L-IFN adenovirus
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07538128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07538128.